Rosa to present at 2012 Keystone Symposia: Cancer and Metabolism

Modeling analysis enables understanding efficacy of large numbers of potential drug combinations.

Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that the results from a recent research project will be presented at the 2012 Keystone Symposia: “Cancer and Metabolism” in Banff, Alberta, Canada on February 13, 2012. Dr. Christiana Friedrich will be presenting a poster entitled “Combination Therapy in Virtual NSCLC Tumor Cells Supports Strategic Development and Treatment Decisions”. The poster will describe the development and use of non-small cell lung cancer in silicocells to explore clinical variability in response to a range of cancer treatments. The main benefit of this approach is that it allows the analysis and prioritization of a large number of potential combination therapies, prior to initiation of expensive and time-consuming studies in humans. This work will also highlight the use of a Tumor PhysioPD™ model to gain additional insight into tumor dynamics and to optimize treatment in a range of in silico tumors.

“This work supports fundamental insights into tumor dynamics in response to therapies and the effects of patient variability,” said Dr. Mike Reed, Rosa’s Vice President of Client Services. “This work lays the foundation for a mechanism-informed personalized medicine approach to optimize cancer treatment in the clinic, and more efficient ways to study large numbers of potential combination therapies.

Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.